New drug comb may lengthen ovarian cancer survival
15th Nov 2006, 03:52 GMT
NEW YORK (Reuters Health) - "Major progress" has been achieved in developing chemotherapy combinations to prolong life in patients with ovarian cancer, according to a team of researchers in Greece, the UK, and the US. The top contender appears to be a combination of two types of cancer drugs -- platinums and taxanes -- administered intraperitoneally (directly into the abdominal cavity).
New drug comb may lengthen ovarian cancer survival related news:
- Babies still an option for those with ovarian cancer? — Blogging Baby
- Other highlights in the November 15 JNCI — EurekAlert! - Biology
- Systemic Treatment Before Surgery For Kidney Cancer Prolongs Patients' Survival — Health News from Medical News Today
- Ovarian Cancer Studies Elusive: Should Erlotinib Be Added to Chemotherapy? — Medscape Hematology-Oncology Headlines
- Recurrent breast cancer: Drug shows promise — The Cancer Blog
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- Cancer drug guidance concern — BBC News | Health | UK Edition
- Executive Q&A: Sara Sinaiko - Helping heal those touched by cancer — madison.com - RSS
- Dismay over cancer drug guidance — BBC News | Latest Published Stories | UK Edition
- NICE rejects use of cancer drug Tarceva — Pharmaceutical Business Review Latest News
Latest news from Reuters: Health:
- Camel milk ice cream to help trim Indian waists
- Diseased gums raise risk of pancreatic cancer
- FDA staff urges new caution on Roche flu drug
- Simple steps can speed heart attack care: study
- Children showing hardening of arteries: U.S. study
- Antibodies destroy HIV-infected cells
- FDA OKs Genentech drug for early breast cancer
- Drug switch improves breast cancer survival: study